Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q4 2025 (December 31)14holders −3
6new positions
8sold out
$1.08avg. 13F price*
At the end of Q4 2025, 14 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, down 3 from Q3 2025. 6 opened new positions and 8 sold out. The largest holders were Angelo Gordon & Co., L.P. ($10.8M), Focus Partners Wealth ($4.1M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.9M).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $6.8M |
| Exits | 8 | $41.2M |
All 13F filers, Q3 2025 → Q4 2025: 11,265,976 shares bought and 4,328,557 shares sold, net +6,937,419 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Angelo Gordon & Co., L.P. | 1.27% | Add +100.0% | 10,000,000 | $10.8M |
| Focus Partners Wealth | 0.00% | New | 3,781,000 | $4.1M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 2,650,000 | $2.9M |
| Rational Advisors, Inc. | 0.29% | New | 2,440,000 | $2.6M |
| Oppenheimer Asset Management Inc. | 0.00% | No change | 175,000 | $189K |
| &partners | 0.00% | No change | 131,000 | $141K |
| Mariner, LLC | 0.00% | No change | 59,000 | $64K |
| Stephens Inc. | 0.00% | No change | 53,000 | $57K |
| Commonwealth Equity Services, LLC | 0.00% | New | 20,000 | $22K |
| MML Investors Services, LLC | 0.00% | New | 18,000 | $19K |
| MAI Capital Management | 0.00% | No change | 15,000 | $16K |
| Cetera Investment Advisers | 0.00% | Reduce -89.8% | 12,000 | $13K |
| CoreCap Advisors, LLC | 0.00% | New | 5,000 | $5K |
| Laffer Tengler Investments, Inc. | 0.00% | New | 1,976 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.